When a causative drug is administered during an ongoing viral infection, increased infiltration of inflammatory CD4+ and CD8+ T-cells into the skin may lead to enhanced production of inflammatory cytokines such as IL-8 and IL-36, potentially triggering AGEP [2-4,8,20]. The gene discussed is CD8A; the disease is viral infectious disease.